SPARC and neoplasm: TAM-expressed stabilin-1 positively correlates with immune checkpoint therapy resistance and T-cell dysfunction in various cancers [199] and, mechanistically, has been shown to promote tumour progression in an in vivo model of breast cancer by scavenging anti-tumour factor, and secreted protein, acidic and rich in cysteine (SPARC) [198].